Gland Pharma Shares in Focus; Board Approves Deepak Sapra as Chief Executive Officer (CEO)

Gland Pharma has approved the appointment of Deepak Sapra as Chief Executive Officer, subject to his acceptance of the company’s offer. He will join the company on November 16, 2026, according to an exchange filing dated August 14, 2026. 

The board approved the appointment following a recommendation from the Nomination and Remuneration Committee. 

Current Position at Dr Reddy’s Laboratories 

Sapra is currently Chief Executive Officer – API and Services at Dr Reddy’s Laboratories and is a Board Member of Aurigene Pharma Services. He has 27 years of executive experience, including 23 years in pharmaceuticals. 

At Dr Reddy’s, he handles global portfolio strategy and a B2B business covering generics, CDMO services, APIs, collaborations, public health and patient access. His responsibilities cover the US, European Union, Japan, Brazil, China, Mexico, the Middle East and Africa. 

International Experience Across Countries  

Sapra’s experience includes business development, licensing, mergers and acquisitions and market expansion across India, the US, Europe, Latin America, Africa, China, Japan and Asia-Pacific. 

His background also covers partnerships, sales and marketing, supply chain management, R&D, operations, portfolio strategy, and access-led partnerships. 

Earlier Roles Held 

Before his current position, Sapra was Chief Executive Officer – Custom Pharmaceutical Services, where he led a CDMO business serving innovator pharmaceutical companies in the US, Europe and Japan. 

Between 2011 and 2015, he held the roles of Vice President – Global Generics Business Development and Senior Director – Global Generics Portfolio Management. 

Education Background  

As per the filing, Sapra holds a Bachelor’s degree in Mechanical Engineering from the Indian Railways Institute of Mechanical and Electrical Engineering, Jamalpur, and a Master’s degree in Management from IIM Bangalore.  

He was a Chevening Scholar at the University of Bradford and a Fulbright Fellow at Carnegie Mellon University. 

Read More: Government Plans To Initiate Offer for Sale in Hindustan Zinc, Hindustan Copper, Mazagon Dock, and Irctc in FY27! 

Gland Pharma Share Price Performance 

As of August 14, 2026, 11:29 am, Gland Pharma share price was trading at ₹2,975.60, a 0.27% increase from the previous closing price. 

Conclusion 

The appointment will take effect from November 16, 2026, subject to acceptance. The filing states that disclosure of relationships between directors is not applicable. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.   
 
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.